Tag: Synaffix
Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering
In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).
South Korean Chong Kun Dang Pharm Licenses Synaffix Platform Technology
South Korean's Chong Kun Dang Pharm (CKD) has entered a licensing agreement with Netherlands-based Synaffix for the development of novel antibody-drug conjugates (ADCs) with best-in-class therapeutic index.
Amgen and Synafix Sign US $2 Billion License Agreement
Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...
Hummingbird Bioscience Signs US $ 150 m License Agreement with Synaffix
Hummingbird Bioscience and Synaffix have entered in a US $150 million license agreement. Under the term of the agreement Synaffix will provide Hummingbird Bioscience with access to its proprietary ADC technologies, including GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads. In turn, Synaffix will be eligible to receive up upfront and milestone payments, plus royalties on net sales.
Kyowa Kirin Expands License Agreement with Synaffix
Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...
Synaffix Expands Licensing Agreement with Mersana
The Netherlands-based Synaffix, a biotechnology company focusing on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed the expansions of...
The 7th Annual World ADC Awards Winners – What’s Next
The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and...
In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to...
In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at Synaffix showed early in vivo...
Synaffix and ADC Therapeutics Expand Collaboration
The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement
Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...
